782 reports of this reaction
2.2% of all IMATINIB reports
#8 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #8 most commonly reported adverse reaction for IMATINIB, manufactured by Mylan Pharmaceuticals Inc.. There are 782 FDA adverse event reports linking IMATINIB to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 2.2% of all 35,081 adverse event reports for this drug.
Patients taking IMATINIB who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is a less commonly reported adverse event for IMATINIB, but still significant enough to appear in the safety profile.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for IMATINIB:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 782 FDA reports for IMATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 2.2% of all adverse event reports for IMATINIB, making it a notable side effect.
If you experience malignant neoplasm progression while taking IMATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.